RezafunginRezafungin is a novel molecule in the echinocandin class of antifungals. The ReSTORE clinical trial protocol is modeled after our Phase 2 STRIVE clinical trial. We expect this trial to enroll approximately 184 evaluable patients. The primary efficacy outcome for the FDA and EMA is fungal-free survival at day 90. Our lead Cloudbreak candidates are AVCs for the prevention and treatment of influenza. RezafunginWe acquired rezafungin, a novel echinocandin antifungal agent, in 2014. The rates of serious adverse events were 43.2%, 52.8%, and 42.6%, respectively. Rezafungin underwent minimal metabolism in human subjects. This is a potentially transformative approach, distinct from current approaches. The influenza virus can cause mild to severe illness, and at times can lead to death. We also rely on trade secrets that may be important to the development of our business. The FDA may request additional information rather than accept an NDA for filing. Insurance coverage is increasingly expensive. Many of these third parties may terminate their engagements with us at any time. We do not have any manufacturing facilities. We have limited intellectual property rights outside the United States. We do not maintain "key person" insurance for any of our executives or employees. Any return to stockholders will therefore be limited to the appreciation of their stock. As a public company, we incur significant legal, accounting and other expenses. Accordingly, both state and federal courts have jurisdiction to entertain such claims.
